Cancer Biopsy Market Share, Size, Trends, Industry Analysis Report, By Type (Liquid, Biopsy, Tissue Biopsy, and Others); By Product Type; By Application; By Region; Segment Forecast, 2024- 2032
- Published Date:Nov-2023
- Pages: 117
- Format: PDF
- Report ID: PM4004
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
The global cancer biopsy market size and share was valued at USD 26.55 billion in 2023 and is expected to grow at a CAGR of 14.8% during the forecast period.
Cancer biopsy stands as a foundation in the field of oncology, offering invaluable insights into the nature, characteristics, and progression of malignancies. This diagnostic procedure involves the extraction of a tissue or fluid sample from a suspicious mass or lesion, which is then analyzed under a microscope or through advanced molecular techniques. The information garnered from a biopsy is instrumental in making accurate diagnoses, determining the cancer's stage, and tailoring personalized treatment plans for patients.
There are various types of biopsy procedures offered by the cancer biopsy market key players. These include needle biopsy, endoscopic biopsy, skin biopsy, bone marrow biopsy, and surgical biopsy. Needle biopsy involves inserting a special needle into the skin through the suspicious area to collect cells. During the endoscopic biopsy procedure, the healthcare professional uses a flexible tube to examine the structure inside the body. After that, special tools are passed through the hollow tube to take a sample of tissue to be examined.
Skin biopsy involves removing cells from the body’s surface. This procedure is widely used to diagnose various skin conditions, such as melanoma and other cancers. The samples of tissues or cells needed for cancer biopsy can be taken from almost any part of the body. Biopsy involves the application of local or general anesthesia, depending on the severity of the case. Cancer biopsy is used to diagnose several cancers, including breast cancer, cervical cancer, lung cancer, or colorectal cancer. The growing prevalence of cancer cases worldwide is driving the market demand forward.
The report provides information on cancer biopsy market revenue and sales at the global, national and regional levels. Besides, it includes a detailed segmentation of the market, primarily based on types, applications, end-uses and regions. The segmentation helps businesses and stakeholders plan their products, finances and business strategies by considering the upcoming development rate for every segment.
To Understand More About this Research: Request a Free Sample Report
The primary driving factor behind cancer biopsy lies in its pivotal role in providing accurate and specific diagnostic information. Biopsies offer a direct sampling of suspect tissues or fluids, allowing pathologists to scrutinize cellular and molecular characteristics. This precision distinguishes between benign and malignant conditions, identifies cancer types, and aids in staging, all of which are crucial for determining appropriate treatment strategies.
Moreover, the advent of molecular profiling techniques like next-generation sequencing (NGS) has propelled the field forward, enabling the identification of genetic alterations driving cancer growth. This information is instrumental in tailoring therapies, known as targeted treatments, that address the specific genetic abnormalities of the tumor. As a result, cancer biopsies have become an indispensable tool, allowing for personalized medicine approaches that optimize treatment efficacy and minimize potential side effects, ultimately leading to improved patient outcomes and survival rates.
- For instance, in June 2023, IMBdx and AstraZeneca extended their collaborative agreement, focusing on advancing the shift from tissue-based to liquid biopsy diagnostics. This development comes after the positive evaluation of a blood-based genomic profiling assay in the context of prostate cancer.
However, one significant restraint in cancer biopsy is the invasiveness of the procedure. Traditional biopsy methods often involve the insertion of a needle or surgical removal of tissue, which can be uncomfortable and carry some degree of risk. This may deter some patients from undergoing the procedure, potentially delaying diagnosis and treatment initiation.
Furthermore, accessibility and availability of advanced biopsy techniques can be a limiting factor. In certain regions or healthcare settings, access to specialized equipment and trained personnel for performing complex biopsies may be limited, leading to disparities in care.
The market research report offers an in-depth analysis of the industry to support informed decision-making. It offers a meticulous breakdown of various market niches and keeps readers updated on the latest industry developments. Along with tracking the Cancer Biopsy Market on the basis of SWOT and Porter’s Five Forces models, the research report includes graphs, tables, charts, and other pictorial representations to help readers understand the key insights and important data easily.
Growth Drivers
- Increase in cancer cases is projected to spur product demand.
The cancer biopsy market is expected to witness significant growth in the coming years, due to the rising number of elderly people and an increase in cancer cases. The emergence of liquid biopsy techniques is also expected to accelerate the market growth. Oncology diagnostics include various procedures such as skin, needle, bone marrow, endoscopic, and surgical biopsies, among which needle biopsies are preferred for early detection. Fine needle aspiration biopsies are also gaining popularity due to their reduced invasiveness and faster results, contributing significantly to the expansion of the cancer biopsy market.
Continuous advancements in biopsy techniques, molecular profiling technologies, and data analysis methods are improving the precision, speed, and comprehensiveness of information derived from biopsies. These technological leaps are reinforcing the crucial role of biopsies in both the diagnosis and treatment of cancer.
Report Segmentation
The market is primarily segmented based on type, product type, application, and region.
|
By Type |
By Product Type |
By Application |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Type Analysis
- Liquid biopsy segment is expected to witness the highest growth during the forecast period
The liquid biopsy segment is projected to grow at a CAGR during the projected period. In recent years, there has been a noticeable surge in physician preference for liquid biopsies. This is largely attributed to their capability to provide insights into diseases from both primary and distant tumor sites. This method plays a pivotal role in personalized medicine treatments, involving the recurrent sampling of tumor markers to adapt therapy according to the patient's response. Additionally, companies are integrating liquid biopsy with advanced Artificial Intelligence (AI) technology for enhanced scrutiny of DNA mutations.
In 2022, tissue biopsy emerged as the leading revenue generator in the field of biopsy procedures, and it remains an essential component of various cancer diagnostic applications. The reason for its continued popularity can be attributed to extensive research efforts that have been focused on evaluating the safety and effectiveness of this procedure. These endeavors have played a vital role in sustaining the dominance of this segment in the global market, a trend that is expected to continue throughout the forecast period.
By Product Type Analysis
- Kits and consumables segment accounted for the largest market share in 2022
The kits and consumables segment held the largest market share in 2022 and is expected to maintain its position throughout the forecast period. These components play a crucial role in several stages of biopsy procedures, and significant investments by industry leaders have further enhanced their importance. Moreover, the increasing number of patients seeking precise, efficient, and quick instruments and kits globally has significantly boosted their demand. The field of cancer biopsy has made notable advancements in terms of instruments, kits, and consumables, reflecting the ongoing progress in this domain.
By Application Analysis
- Breast cancer held a significant market revenue share in 2022
The breast cancer segment held a significant market share in revenue share in 2022. Breast cancer stands as a pivotal focus within the cancer biopsy market, given its high prevalence rate, particularly affecting 1 in 8 U.S. women. The alarming statistics highlight the critical need for accurate and timely diagnosis. Microscopic analysis of breast tissue, obtained through needle or surgical biopsies, plays a crucial role in providing definitive diagnoses, staging, and characterizing the type of breast cancer. The prominence of breast cancer within the biopsy market underscores the pivotal role biopsies play in the detection and management of this prevalent and impactful malignancy.
Regional Insights
- North America region dominated the global market in 2022
The North America region dominated the global market with the largest market share in 2022 and is expected to maintain its dominance over the anticipated period. The cancer biopsy market in North America is characterized by advanced healthcare infrastructure and extensive R&D activities. In 2022, it held a significant market share, driven by a well-established healthcare system and early adoption of cutting-edge technologies. The region's high prevalence of cancer cases and growing geriatric population further contribute to its prominence. Moreover, collaborations between key industry players and research institutions accelerate advancements in biopsy technologies. The introduction of innovative techniques, like liquid biopsies, also gains traction, offering non-invasive alternatives for cancer detection. North America remains a pivotal region, shaping the landscape of cancer diagnostics through biopsy procedures.
The cancer biopsy market in the Asia-Pacific region is witnessing steady growth, driven by increasing healthcare infrastructure and rising cancer prevalence. With a burgeoning population, there's a heightened demand for advanced diagnostic tools. Moreover, awareness campaigns and improved access to healthcare services have amplified the number of cancer screenings. The adoption of biopsy procedures is on the rise, aiding in early and accurate cancer diagnoses. While the market is evolving, there is still untapped potential, particularly in terms of technological advancements and accessibility to cutting-edge biopsy techniques. As the region continues to develop, the cancer biopsy market is poised for significant expansion in the Asia-Pacific.
Key Market Players & Competitive Insights
The cancer biopsy market is fragmented and is anticipated to witness competition due to several players' presence. Major service providers in the market are constantly upgrading their technologies to stay ahead of the competition and to ensure efficiency, integrity, and safety. These players focus on partnership, product upgrades, and collaboration to gain a competitive edge over their peers and capture a significant market share.
Some of the major players operating in the global market include:
- Abbott Laboratories
- Becton, Dickinson, and Company
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Illumina, Inc.
- Koninklijke Philips N.V.
- Myriad Genetics, Inc.
- NeoGenomics, Inc.
- QIAGEN N.V.
- Siemens Healthineers AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Veracyte, Inc.
Recent Developments
- In January 2023, C2i Genomics, a prominent cancer intelligence company, announced its expansion into the European market through a strategic partnership with OncoDNA, a company specializing in precision medicine for patients with cancer and genetic disorders. Their shared goal is to advance the field of personalized medicine for individuals who are dealing with cancer and hereditary conditions.
Cancer Biopsy Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 30.42 billion |
|
Revenue Forecast in 2032 |
USD 92.09 billion |
|
CAGR |
14.8% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments Covered |
By Type, By Product Type, By Application, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
Delve into the intricacies of the Cancer Biopsy Market in 2024 through the meticulously compiled market share, size, and revenue growth rate statistics by Polaris Market Research Industry Reports. Uncover a comprehensive analysis that not only projects market trends up to 2032 but also provides valuable insights into the historical landscape. Immerse yourself in the depth of this industry analysis by acquiring a complimentary PDF download of the sample report.
Browse Our Top Selling Reports
Pneumatic Conveying Systems Market Size, Share 2024 Research Report
Health & Hygiene Packaging Market Size, Share 2024 Research Report
Spinal Implants Market Size, Share 2024 Research Report
Polyethylene Furanoate (PEF) Market Size, Share 2024 Research Report
Oil Immersed Power Transformer Market Size, Share 2024 Research Report
© 2024 Polaris Market Research and Consulting. All rights reserved
